Philip Morris International Holds ‘Open Mic’ at 2019 Cannes Lions Festival
Philip Morris International (PMI) (NYSE: PM) announced today its return to the Cannes Lions International Festival of Creativity to engage with those who are actively creating and shaping meaningful change in the world. Working from its central theme of “Open Mic,” PMI will foster conversations around unexpected and provocative ideas, concepts and views with some of today’s boldest thinkers at the gathering known for bringing together the world’s most creative people to discuss new ideas, pioneering research and emerging technologies that help make and shape popular culture.
“For PMI, attending Cannes is a surprising juxtaposition of what people may expect of us. But that’s what we need to do as we strive to unsmoke the world: be bold, cut through the haze and have conversations about the future,” said Jacek Olczak, chief operating officer for PMI.
Returning to Cannes for the second year in a row, PMI will host a series of panels, one-on-one conversations and events that focus on encouraging productive discourse and change. Led by the creative industry’s Bonin Bough, discussions will take place with PMI representatives as well as some of the world’s most progressive conversationalists and thought leaders, including Robin Wright, Rose McGowan, Cindy Gallop, and Wyclef Jean, among others.
Sample discussion topics include:
- Being Bold and Unapologetic Against What Society Expects
- The Future Is Not “Reality,” but “Real”
- Gender Equality in Ad-land
- Inclusion and Diversity: Who Gets Included
- Influences of Change: How Today’s Rapid and Constant State of Change Will Look in 2020
- Digital Conversations Around Mindfulness, Culture and Purpose
- A New Era: Content, Creative and Data
- How Brands Are Promoting Social Values
- Emerging Trends: Technology Defines Culture, and in Turn, Culture Defines Technological Development
Located at L’Ondine, 64 Boulevard de la Croisette for the duration of the festival, the PMI pavilion will welcome all registered festival attendees to attend “Open Mic” events each day.
PMI is undergoing one of the industry’s most disruptive transformations, both internally and externally. Committed to “unsmoking” the world, PMI is steadily re-entering civil society to create a smoke-free future. To learn more about the company’s transformation, visit www.PMI.com
About Philip Morris International: Delivering a Smoke-Free Future
Philip
Morris International (PMI) is leading a transformation in the tobacco
industry to create a smoke-free future and ultimately replace cigarettes
with smoke-free products to the benefit of adults who would otherwise
continue to smoke, society, the company and its shareholders. PMI is a
leading international tobacco company engaged in the manufacture and
sale of cigarettes, smoke-free products and associated electronic
devices and accessories, and other nicotine-containing products in
markets outside the U.S. PMI is building a future on a new category of
smoke-free products that, while not risk-free, are a much better choice
than continuing to smoke. Through multidisciplinary capabilities in
product development, state-of-the-art facilities and scientific
substantiation, PMI aims to ensure that its smoke-free products meet
adult consumer preferences and rigorous regulatory requirements. PMI’s
smoke-free product portfolio includes heat-not-burn and
nicotine-containing vapor products. As of March 31, 2019, PMI estimates
that approximately 7.3 million adult smokers around the world have
already stopped smoking and switched to PMI’s heat-not-burn product,
which is currently available for sale in 47 markets in key cities or
nationwide. For more information, please visit www.pmi.com
and www.pmiscience.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005047/en/
Contact information
Ryan Sparrow
Philip Morris International Media Office
T. +41
(0) 79 242 4500
E. ryan.sparrow@pmi.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin